^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS mutation + PD-L1 expression

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126; 3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    11ms
    The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation. (PubMed, Therap Adv Gastroenterol)
    The median age was 68.0 years; 47 patients (75.8%) received pembrolizumab and 15 (24.2%) received nivolumab as salvage therapy. All patients received gemcitabine plus cisplatin as the frontline therapy, and 53.2% received fluoropyrimidine plus oxaliplatin (FOLFOX) before ICI...This finding was not shown in patients with wild-type KRAS. Our analysis suggested that PD-L1 expression might be a useful biomarker for ICIs in BTC patients with KRAS mutation but not in those with wild-type KRAS.
    Checkpoint inhibition • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • PD-L1 negative • KRAS wild-type • RAS wild-type • KRAS mutation + PD-L1 expression
    |
    TruSight Oncology 500 Assay
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium
    12ms
    Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma. (PubMed, Lung Cancer)
    PEAC is a disease of genetic heterogeneity. The administration of EGFR and ALK inhibitors was effective in patients with PEAC. PD-L1 expression and KRAS mutation type may be used as predictive biomarkers for immunotherapy in PEAC. This study provided both theoretical basis and clinical evidence for PEAC.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • mTOR (Mechanistic target of rapamycin kinase) • PI3K (Phosphoinositide 3-kinases)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • ALK rearrangement • KRAS G12V • ALK mutation • KRAS G12A • KRAS G12 • MTOR mutation • KRAS mutation + PD-L1 expression
    |
    Tagrisso (osimertinib) • Ensacove (ensartinib)
    1year
    The Efficacy of Immune Checkpoint Inhibitors in Advanced Biliary Tract Cancer with KRAS Mutation (AACR 2023)
    47 patients (75.8%) received pembrolizumab and 15 (24.2%) received nivolumab as salvage therapy. All patients received gemcitabine plus cisplatin as the frontline therapy, and 53.2% had fluoropyrimidine plus oxaliplatin (FOLFOX) before ICIs...In subgroup analysis, patients with both KRAS mutation and PD-L1 positivity had longer PFS as compared to patients with KRAS mutation and PD-L1 negativity (6.5 vs 2.6 months, p=0.047). This finding was not shown in patients with a wild type of KRAS.ConclusionThis analysis showed that PD-L1 expression might be a novel biomarker for ICIs in BTC patients with KRAS mutation but not the wild type of KRAS.
    Clinical • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • PD-L1 negative • KRAS wild-type • KRAS mutation + PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium
    over1year
    The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation. (ASCO-GI 2023)
    47 patients (75.8%) received pembrolizumab and 15 (24.2%) received nivolumab as salvage therapy. All patients received gemcitabine plus cisplatin as the frontline therapy, and 53.2% had fluoropyrimidine plus oxaliplatin (FOLFOX) before ICIs... The PD-L1 expression might be a novel biomarker for ICIs in BTC patients with KRAS mutation but not in those with the wild type of KRAS.
    Clinical • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • KRAS mutation • PD-L1 negative • KRAS wild-type • KRAS mutation + PD-L1 expression • KRAS mutation + PD-L1 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium
    2years
    KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. (PubMed, Cancer Cell Int)
    Our results suggest that ERK signaling inhibition contributes to the reduction of PD-L1 expression through the autophagy pathway in iCCA. As a supplement to anti-PD-1/PD-L1 immunotherapy, ERK-targeted therapy may serve as a potentially novel treatment strategy for human KRAS-mutated iCCA.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • ATG7 (Autophagy Related 7)
    |
    PD-L1 expression • KRAS mutation • KRAS mutation + PD-L1 expression